Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor

被引:29
作者
Heise, Christopher E. [1 ]
Sullivan, Susan K.
Crowe, Paul D.
机构
[1] Neurocrine Biosci Inc, San Diego, CA USA
[2] Synteract Inc, Carlsbad, CA USA
关键词
GPCR; kinetics; SPA; HTS; SAR;
D O I
10.1177/1087057106297362
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Many nonpeptide antagonists of the gonadotropin-releasing hormone (GnRH) receptor, as well as other drug targets, possess a broad range of dissociation kinetic rate constants. Current methods to accurately define kinetic rate parameters such as K-on and K-off are time and labor intensive, prompting the development of a screening assay to identify slowly dissociating compounds for follow-up rate constant determination. The authors measured inhibition binding constants (K) for GnRH receptor antagonists after 30 min and 10 h of incubation and observed several compounds with markedly decreased K, values over time (Ki(30 min)/Ki (10 h) > 6). They used scintillation proximity assay technology to perform these binding experiments because this homogeneous assay does not have a fixed termination end point as does filtration binding, permitting successive readings to be taken from the same assay plate over an extended period of time. They also used a quantitative method of kinetic rate analysis to confirm that a large disparity between a compound's K-i value at 30 min and 10 h could identify compounds that dissociate slowly. Thus, the K-i ratio can be used to screen for and select compounds to test using more quantitative, albeit lower throughput methods to accurately define kinetic rate constants.
引用
收藏
页码:235 / 239
页数:5
相关论文
共 17 条
[1]   Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats [J].
Anderes, KL ;
Luthin, DR ;
Castillo, R ;
Kraynov, EA ;
Castro, M ;
Hood, KN ;
Gregory, ML ;
Pathak, VP ;
Christie, LC ;
Paderes, G ;
Vazir, H ;
Ye, Q ;
Anderson, MB ;
May, JM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (02) :688-695
[3]  
Bakris G, 2001, J Clin Hypertens (Greenwich), V3, P16, DOI 10.1111/j.1524-6175.2001.00826.x
[4]  
Berry Jenny, 2005, Methods Mol Biol, V306, P121
[5]   Opinion - Drug-target residence time and its implications for lead optimization [J].
Copeland, Robert A. ;
Pompliano, David L. ;
Meek, Thomas D. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :730-739
[6]   Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists [J].
Hoare, SRJ ;
Sullivan, SK ;
Ling, N ;
Crowe, PD ;
Grigoriadis, DE .
MOLECULAR PHARMACOLOGY, 2003, 63 (03) :751-765
[7]   Determining the potency and molecular mechanism of action of insurmountable antagonists [J].
Kenakin, Terry ;
Jenkinson, Stephen ;
Watson, Christian .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (02) :710-723
[8]   A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients -: A placebo-controlled, forced titration study [J].
Lacourcière, Y ;
Asmar, R .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (12) :1181-1187
[9]  
MOTULSKY HJ, 1984, MOL PHARMACOL, V25, P1
[10]   Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism [J].
Sullivan, Susan K. ;
Hoare, Sam R. J. ;
Fleck, Beth A. ;
Zhu, Yun-Fei ;
Heise, Christopher E. ;
Struthers, R. Scott ;
Crowe, Paul D. .
BIOCHEMICAL PHARMACOLOGY, 2006, 72 (07) :838-849